ClinicalTrials.gg
RecruitingNCT02784210Updated Oct 5, 2026

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

A Phase 2 interventional study of Methylprednisolone and Prednisone in Multiple Sclerosis, sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2016; still recruiting 10 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing methylprednisolone in Multiple Sclerosis — 1 open to participants now, 1 under way, none of them phase 3. Methylprednisolone · Multiple Sclerosis.

Planned enrollment
7th of 14
30 · median 30
Started
2016
the only one that year
Phase 2
4 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
National Institute of Neurological Disorders and Stroke (NINDS)

Among the 14 studies testing methylprednisolone in Multiple Sclerosis, this one is the 7th largest by planned enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 12th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 14 studies testing methylprednisolone in Multiple Sclerosis is open now, in 1 country.

By country, each count listing its studies:

About methylprednisolone

Methylprednisolone: first FDA approval 1957 (MEDROL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing methylprednisolone in Multiple Sclerosis, or all of them as a file.
02

Study summary

Background:

Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not heal as well as others. Corticosteroids are the standard treatment to reduce symptoms of MS relapse. But there is no standard treatment for people with enhancing MS lesions without signs of MS relapse. Researchers want to see if a short-term high-dose course of corticosteroids helps heal those lesions.

Objective:

To study the effects of short-term high-dose corticosteroids on ring-enhancing MS.

Eligibility:

Adults ages 18 and older who:

  • Have MS and a rim-enhancing lesion on a prior brain MRI
  • Are enrolled in another NINDS protocol

Design:

Participants will be screened under another protocol

Participants will be randomly assigned to get either no treatment or 3 days of treatment with a corticosteroid.

Participants will have:

  • 1 baseline visit
  • 3 days of high-dose steroids, intravenous or oral. If IV, participants will receive methylprednisolone by IV each day. Participants will also be prescribed medicine to protect their stomach.
  • Follow-up visits will be at week 13 and week 25 after randomization to treatment or no treatment.

Visits include medical history and physical exam. Participants will have blood and urine tests. Participants will also have neurological exams and MRIs. Participants lie on a table that slides into a cylinder. They are in the scanner 1.5-2 hours. They get a dye through a catheter: A needle guides a thin plastic tube into an arm vein.

Read the detailed description

Objectives:

The primary aim of this pilot study is to assess the effects of short-term, high-dose corticosteroid administration on the 12-week evolution of multiple sclerosis lesions with centripetal enhancement pattern on magnetic resonance imaging (MRI), in particular with respect to the development of a hypointense rim on 7-tesla phase images. In our prior work, the phase rim has been associated with persistent deleterious inflammation with poor repair and ongoing neurodegeneration within lesions.

Study population:

Up to 30 multiple sclerosis patients with asymptomatic contrast-enhancing lesions will be enrolled. Patients are randomly assigned to either 3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day or oral prednisone at 1250 mg/day) or to no treatment.

Design:

This is a single-site study.Patients undergo serial brain MRIs with gadolinium-based contrast agent on both 3- and 7-tesla scanners over an approximate 25-week period. 3-tesla scans are obtained at baseline and week 25. 7-tesla scans are obtained at baseline and at weeks 13 and 25. Participants with one or more centripetal/rim-enhancing lesions at the baseline scan are randomized and followed. Clinical evaluation and blood testing are performed at baseline and weeks 13 and 25.

Outcome measures:

The primary outcome measure is the presence or absence, on the week-13 7-tesla scan, of a hypointense phase rim in each of the lesions followed over time. Secondary outcome measures include the presence or absence of a hypointense phase rim at week 25, as well as the lesion volume and intralesional median R1 relaxation rate at weeks 13 and 25. From 3-tesla scans, we will measure the change in normalized intralesional proton density-weighted and T1-weighted signal, as well as the R1 relaxation rate, between baseline and week 25. We will also assess for the presence or absence of a hypointense phase at 3T. Additional exploratory outcome measures, including clinical and immunological assessments, will also be collected.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Centripetal Enhancement
  • MRI
  • 7 Tesla
  • Gadolinium
  • MS
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple sclerosis, as defined by the 2017 Revised McDonald Criteria;
  • Age 18 or older;
  • Ability to provide ;
  • Able to participate in study procedures and provide high-quality clinical research and imaging data, based on limited artifacts on prior MRI scans and, when possible to determine;
  • Presence of a gadolinium enhancing lesion on the screening (3T or 7T) brain MRI that demonstrates either centripetal/rim enhancement or a phase rim, or both;
  • Simultaneously participates in another screening or natural history protocol within the NINDS Neuroimmunology Clinic at the time of study entry.
  • Willing to use if able to conceive a child

Exclusion criteria

EXCLUSION CRITERIA:

  • Medical for MRI (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects, or body piercings that are not MRI-compatible or cannot be removed);
  • Psychological contraindications for MRI (e.g., claustrophobia), to be assessed at the time the medical history is collected;
  • Treatment with systemic in previous 30 days (non-systemic administration of steroids, such as topical or local injection, is acceptable);
  • Experiencing new neurological symptoms, with onset in previous 2 weeks, attributable to MS relapse;
  • Pregnancy or current breastfeeding;
  • Screening labs, only if required per current NIH Clinical Center guidelines for kidney-function screening before gadolinium-based MRI contrast, demonstrating estimated \<60 mL/min;
  • Known to gadolinium-based contrast agents;
  • Medical contraindications to corticosteroid administration (e.g., diabetes, gastric ulcer)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Methylprednisolone

    3 day course of intravenous methylprednisolone 1000 mg/day

    Drug: Methylprednisolone

  • Experimental
    prednisone

    3-day course of oral prednisone 1250 mg/day

    Drug: Prednisone

Interventions

  • 3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day

  • 3 days of corticosteroids (oral prednisone at 1250 mg/day

06

What researchers measure

Primary outcomes

  1. the presence or absence of a hypointense phase rim around each lesion followed over time

    At week 13, the presence or absence of a hypointense phase rim around each lesion followed over time.

    Time frame: at 13 weeks

Secondary outcomes

  1. The change in normalized intralesional proton density-weighted and T1-weighted signal, as well as the R1 relaxation rate, from 3T scan.

    From 3-tesla scans, we willmeasure the change in normalized intralesional proton density-weighted and T1-weighted signal, as wellas the R1 relaxation rate, between baseline and week 25.

    Time frame: week 25

  2. The presence or absence of a 3T hypointense phase rim around each lesion

    The presence or absence of a 3T hypointense phase rim around each lesion at week and 25

    Time frame: at week 25

  3. The presence or absence of a hypointense phase rim around each lesion followed over time.

    At week 25, the presence or absence of a hypointense phase rim around each lesion followed over time.

    Time frame: at week 25

  4. Lesion volume and intralesional median R1 relaxation rate as determined from the 7T MP2RAGE scan,

    Lesion volume and intralesional median R1 relaxation rate at weeks 13 and 25, as determined from the 7T MP2RAGE scan, comparing corticosteroid and no-treatment groups.

    Time frame: at week 13 and 25

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactprpl@cc.nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that results in publication

Supporting information: Study protocol, Informed consent form

Time frame: 6 months after publication

Access criteria: Will be shared under tech transfer agreements

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Dec 2028, 146 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 146 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2016
First posted
May 27, 2016
StartActual
Oct 5, 2016
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02784210
Responsible party
Sponsor
First posted
May 27, 2016
Start date
Oct 5, 2016
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Daniel S Reich, M.D.
Contact
reichds@ninds.nih.gov
(301) 496-1801
Daniel S Reich, M.D.
principal investigator · National Institute of Neurological Disorders and Stroke (NINDS)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methylprednisolone · Prednisone

Start the discussion